# To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656

> **NCT01083212** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 19 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** AZD1656
- **DRUG:** Gemfibrozil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01083212
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2010-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01083212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01083212, "To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT01083212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*